Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study

Genes Chromosomes and Cancer

Volumn 49, Issue 8, 2010, Pages 733-745

  Gast, Andreas ^a   Scherer, Dominique ^a   Chen, Bowang ^a   Bloethner, Sandra ^a   Melchert, Stephanie ^b   Sucker, Antje ^c   Hemminki, Kari ^a   Schadendorf, Dirk ^c   Kumar, Rajiv ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2;

ARTICLE; CHROMOSOME 13Q; CHROMOSOME 16Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA MICROARRAY; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; GENOME; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE N RAS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR GENE;

ADOLESCENT; ADULT; AGED; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MELANOMA; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953500573     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20785     Document Type: Article

References (50)

1. Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A. 2008. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18:29-35. (Pubitemid 351628053)
2. Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Brocker EB, Straten P, Rapp UR, Becker JC. 2004. Immunogenicity of constitutively active V599EBRaf. Cancer Res 64:5456-5460.
3. Baker GL, Landis MW, Hinds PW. 2005. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 4:330-338.
4. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. 1998. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58:2170-2175. (Pubitemid 28232904)
5. Bloethner S, Chen B, Hemminki K, Muller-Berghaus J, Ugurel S, Schadendorf D, Kumar R. 2005. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26:1224-1232. (Pubitemid 41417899)
6. Bloethner S, Hemminki K, Thirumaran RK, Chen B, Mueller- Berghaus J, Ugurel S, Schadendorf D, Kumar R. 2006. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes. Melanoma Res 16:297-307. (Pubitemid 44090173)
7. Chernoff KA, Bordone L, Horst B, Simon K, Twadell W, Lee K, Cohen JA, Wang S, Silvers DN, Brunner G, Celebi JT. 2009. GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res 15:4288-4291.
8. Chin L, Garraway LA, Fisher DE. 2006. Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 20:2149-2182.
9. Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E. 2005. a-Melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol 175:4806-4813. (Pubitemid 41362024)
10. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147.
11. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Jr, You MJ, Depinho RA, McMahon M, Bosenberg M. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552.
12. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
13. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. 2009. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15:294-303.
14. Dovey M, White RM, Zon LI. 2009. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. Zebrafish 6:397-404.
15. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. 2005. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122.
16. Glatz-Krieger K, Pache M, Tapia C, Fuchs A, Savic S, Glatz D, Mihatsch M, Meyer P. 2006. Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. Virchows Arch 449:328-333.
17. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
18. Hauser JE, Kadekaro AL, Kavanagh RJ, Wakamatsu K, Terzieva S, Schwemberger S, Babcock G, Rao MB, Ito S, Abdel-Malek ZA. 2006. Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment Cell Res 19:303-314.
19. Horst B, Gruvberger-Saal SK, Hopkins BD, Bordone L, Yang Y, Chernoff KA, Uzoma I, Schwipper V, Liebau J, Nowak NJ, Brunner G, Owens D, Rimm DL, Parsons R, Celebi JT. 2009. Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol 174:1524-1533.
20. Hull C, Larson A, Leachman S. 2003. Pharmacogenetic candidate genes for melanoma. Pharmacogenomics 4:753-765.
21. Iivanainen E, Lauttia S, Zhang N, Tvorogov D, Kulmala J, Grenman R, Salven P, Elenius K. 2009. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvasc Res 78:278-285.
22. Jang SW, Yang SJ, Ehlen A, Dong S, Khoury H, Chen J, Persson JL, Ye K. 2008. Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1. Cancer Res 68:4559-4570.
23. Jarvinen AK, Autio R, Kilpinen S, Saarela M, Leivo I, Grenman R, Makitie AA, Monni O. 2008. High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. Genes Chromosomes Cancer 47:500-509. (Pubitemid 351657185)
24. Jonsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringner M, Guldberg P, Borg A. 2007. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 26:4738-4748. (Pubitemid 47067402)
25. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162.
26. Kumar R, Smeds J, Lundh Rozell B, Hemminki K. 1999. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): Homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 9:138-147. (Pubitemid 29331522)
27. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, Hemminki K. 2003a. BRAF mutations in metastatic melanoma: A possible association with clinical outcome. Clin Cancer Res 9:3362-3368. (Pubitemid 37082731)
28. Kumar R, Angelini S, Hemminki K. 2003b. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 22:9217-9224. (Pubitemid 38122033)
29. Kumar R, Angelini S, Snellman E, Hemminki K. 2004. BRAF mutations are common somatic events in melanocytic nevi. J Investig Dermatol 122:342-348. (Pubitemid 38281054)
30. LePape E, Passeron T, Giubellino A, Valencia JC, Wolber R, Hearing VJ. 2009. Microarray analysis sheds light on the dedifferentiating role of agouti signal protein in murine melanocytes via the Mc1r. Proc Natl Acad Sci USA 106:1802-1807.
31. Libe R, Fratticci A, Coste J, Tissier F, Horvath A, Ragazzon B, Rene-Corail F, Groussin L, Bertagna X, Raffin-Sanson ML, Stratakis CA, Bertherat J. 2008. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 14:4016-4024.
32. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M. 2006. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 66:4182-4190.
33. Massi D, Tarantini F, Franchi A, Paglierani M, Di Serio C, Pellerito S, Leoncini G, Cirino G, Geppetti P, Santucci M. 2006. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 19:246-254. (Pubitemid 43117609)
34. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-724.
35. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. 2008. BRAF(E600) in benign and malignant human tumours. Oncogene 27:877-895.
36. Nambiar S, Mirmohammadsadegh A, Hengge UR. 2008. Cutaneous melanoma: Fishing with chips. Curr Mol Med 8:235-243.
37. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. 2005. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65:6071-6079.
38. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS. 2003. High frequency of BRAF mutations in nevi. Nat Genet 33:19-20.
39. Rakosy Z, Vizkeleti L, Ecsedi S, Voko Z, Begany A, Barok M, Krekk Z, Gallai M, Szentirmay Z, Adany R, Balazs M. 2007. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 121:1729-1737.
40. Robinson SJ, Healy E. 2002. Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix. Oncogene 21:8037-8046. (Pubitemid 35430614)
41. Sauter ER, Yeo U-C, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC. 2002. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62:3200-3206. (Pubitemid 34602414)
42. Scherer D, Nagore E, Bermejo JL, Figl A, Botella-Estrada R, Thirumaran RK, Angelini S, Hemminki K, Schadendorf D, Kumar R. 2009. Melanocortin receptor 1 variants and melanoma risk: A study of 2 European populations. Int J Cancer 125:1868-1875.
43. Smalley KS. 2003. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104:527-532.
44. Stark M, Hayward N. 2007. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single- nucleotide polymorphism arrays. Cancer Res 67:2632-2642. (Pubitemid 46548950)
45. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. 2007. Mutant p53: An oncogenic transcription factor. Oncogene 26:2212-2219. (Pubitemid 46536646)
46. Thorvaldsen S. 2005. A tutorial on Markov models based on Mendel's classical experiments. J Bioinform Comput Biol 3: 1441-1460. (Pubitemid 43119059)
47. Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller- Berghaus J, Rittgen W, Hemminki K, Becker JC, Kumar R, Schadendorf D. 2007. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2:e236.
48. Weinstein IB, Joe A. 2008. Oncogene addiction. Cancer Res 68:3077-3080.
49. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. 2008. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 3:e2734.
50. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X. 2009. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol 174:2367-2377.